Program
licaminlimab
Also written as “LME636 60 mg/mL ophthalmic solution” and “LME636 ophthalmic solution”.
Its studies are mostly in Dry Eye Syndromes · Uveitis, Anterior, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Oculis | 21 open or running | phase 3since Apr 16, 2026 | May 31, 2023 | Dec 2026phase 3 · NCT07548632 |
| Alcon | 10 open or running | phase 2since Jun 23, 2015 | Jun 23, 2015 | none ahead |
| Novartis | 10 open or running | phase 2since Feb 13, 2015 | Feb 13, 2015 | none ahead |
Also a collaborator on its studies: ORA.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 13, 2015First study: phase 2 study in Dry Eye SyndromesNew to NovartisNovartis · NCT02365519 · 514 enrolled
- Jun 23, 2015Alcon's first study: phase 2 study in Uveitis, AnteriorNew to AlconAlcon · NCT02482129 · 45 enrolled
- May 31, 2023Oculis's first study: phase 2 study in Dry Eye SyndromesNew to OculisOculis · NCT05896670 · 122 enrolled · United States
- Apr 16, 2026Phase 3 study in Dry Eye SyndromesPhase 3 reachedOculis · NCT07548632 · 160 enrolled · United States
Ahead
- Dec 2026Primary completion: phase 3 study in Dry Eye SyndromesOculis · NCT07548632
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07548632Dry Eye Syndromes · United States | 3 | Active, not recruiting | Oculis | Dec 2026 | 160 |
| NCT05896670Dry Eye Syndromes · United States | 2 | Completed | Oculis | Mar 27, 2024 | 122 |
| NCT02482129Uveitis, Anterior | 2 | Completed | Alcon | Mar 21, 2016 | 45 |
| NCT02365519Dry Eye Syndromes | 2 | Completed | Novartis | Oct 16, 2015 | 514 |
How it is read
Names in the registry
- “licaminlimab”, 2 entries
- “LME636 60 mg/mL ophthalmic solution”, 1 entry
- “LME636 ophthalmic solution”, 1 entry
Conditions, from the studies’ own filings
- Dry Eye Syndromes, 3 studies
- Uveitis, Anterior, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.